MGNX

SEC source: 0001125345-23-000096 · wk-form4_1685739273.xml · derivative · entry 1

STUMP DAVID C · CIK 0001191235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000095 · wk-form4_1685739198.xml · derivative · entry 2

HEIDEN WILLIAM K · CIK 0001214939 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan.

F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

SEC source: 0001125345-23-000095 · wk-form4_1685739198.xml · derivative · entry 1

HEIDEN WILLIAM K · CIK 0001214939 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000094 · wk-form4_1685739126.xml · derivative · entry 3

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,490

Underlying: Common Stock · 21,490 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

F4 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000094 · wk-form4_1685739126.xml · derivative · entry 2

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan.

F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

SEC source: 0001125345-23-000094 · wk-form4_1685739126.xml · derivative · entry 1

SIEGEL JAY PHILIP · CIK 0001722857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 3

Chhabra Meenu · CIK 0001534200 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-05-31

F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 2

Chhabra Meenu · CIK 0001534200 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,759

Underlying: Common Stock · 15,759 shares

Expires 2033-05-31

F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

F4 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000093 · wk-form4_1685739001.xml · derivative · entry 1

Chhabra Meenu · CIK 0001534200 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan.

F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

SEC source: 0001125345-23-000092 · wk-form4_1685738415.xml · derivative · entry 2

O'Brien Federica F. · CIK 0001140119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan.

F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

SEC source: 0001125345-23-000092 · wk-form4_1685738415.xml · derivative · entry 1

O'Brien Federica F. · CIK 0001140119 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2033-05-31

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000054 · wf-form4_167882533470011.xml · nonDerivative · entry 1

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $5.80 to $6.18. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · derivative · entry 3

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

F1 · derivative.exercise_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

F1 · derivative.expiration_date: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

SEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · nonDerivative · entry 2

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,372

SEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · nonDerivative · entry 1

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

SEC source: 0001125345-23-000040 · wf-form4_167727445351772.xml · derivative · entry 3

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 22, 2022 the reporting person was granted 37,500 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

F1 · derivative.exercise_date: On February 22, 2022 the reporting person was granted 37,500 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

F1 · derivative.expiration_date: On February 22, 2022 the reporting person was granted 37,500 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

SEC source: 0001125345-23-000040 · wf-form4_167727445351772.xml · nonDerivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,180

SEC source: 0001125345-23-000040 · wf-form4_167727445351772.xml · nonDerivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,799

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 22, 2022 the reporting person was granted 37,500 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis.

SEC source: 0001125345-23-000037 · wf-form4_167666948789460.xml · derivative · entry 2

Koenig Scott · CIK 0001587514 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,000

Underlying: Common Stock · 127,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000037 · wf-form4_167666948789460.xml · derivative · entry 1

Koenig Scott · CIK 0001587514 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 510,000

Underlying: Common Stock · 510,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000036 · wf-form4_167666944263121.xml · derivative · entry 2

Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000036 · wf-form4_167666944263121.xml · derivative · entry 1

Spitznagel Thomas · CIK 0001675464 · Sr VP, Technical Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000035 · wf-form4_167666940392252.xml · derivative · entry 2

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000035 · wf-form4_167666940392252.xml · derivative · entry 1

Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000034 · wf-form4_167666936780166.xml · derivative · entry 2

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000034 · wf-form4_167666936780166.xml · derivative · entry 1

Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000032 · wf-form4_167666929868389.xml · derivative · entry 2

Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000032 · wf-form4_167666929868389.xml · derivative · entry 1

Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000033 · wf-form4_167666933832934.xml · derivative · entry 2

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000033 · wf-form4_167666933832934.xml · derivative · entry 1

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000031 · wf-form4_167666926287264.xml · derivative · entry 2

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000031 · wf-form4_167666926287264.xml · derivative · entry 1

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-23-000030 · wf-form4_167666919685342.xml · derivative · entry 2

Eck Stephen L. · CIK 0001669041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.

SEC source: 0001125345-23-000030 · wf-form4_167666919685342.xml · derivative · entry 1

Eck Stephen L. · CIK 0001669041 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.

SEC source: 0000899243-23-005209 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,579,963

SEC source: 0000899243-23-002378 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,079,963

SEC source: 0001125345-23-000019 · wf-form4_167295491283833.xml · derivative · entry 1

Chhabra Meenu · CIK 0001534200 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-23-000017 · wf-form4_167295474579736.xml · derivative · entry 1

Liu Margaret · CIK 0001324059 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2033-01-03

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,929,963

SEC source: 0000899243-22-039423 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,729,963

SEC source: 0000899243-22-036996 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,529,963

SEC source: 0001125345-22-000094 · wf-form4_166724856876840.xml · derivative · entry 2

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,500 shares

Expires 2023-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.

SEC source: 0001125345-22-000094 · wf-form4_166724856876840.xml · nonDerivative · entry 1

Risser Eric Blasius · CIK 0001587774 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,229,963

SEC source: 0000899243-22-034118 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,979,963

SEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 2

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,729,963

SEC source: 0000899243-22-033943 · doc4.xml · nonDerivative · entry 1

BIOTECH TARGET N V · CIK 0001259870 · 10% owner

BB BIOTECH AG · CIK 0000924223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,443,986

SEC source: 0001125345-22-000075 · wf-form4_165549709974837.xml · nonDerivative · entry 1

Karrels James · CIK 0001587477 · SVP, CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,776

F1 · price: This transaction was executed in multiple trades at prices ranging from $2.435 to $2.50. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F2 · ownership.direct: Owned jointly with reporting person's wife.

SEC source: 0001125345-22-000073 · wf-form4_165342417498958.xml · derivative · entry 1

HEIDEN WILLIAM K · CIK 0001214939 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

Underlying: Common Stock · 36,000 shares

Expires 2032-05-23

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/36th increments (rounded upwards for whole shares) beginning one month from the date of grant.

SEC source: 0001125345-22-000068 · wf-form4_165335446035323.xml · derivative · entry 1

STUMP DAVID C · CIK 0001191235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-05-19

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.